Fenwick corporate partner Effie Toshav was named Corporate Lawyer of the Year at the 2020 LMG Life Sciences Americas Awards. These annual awards recognize lawyers from across the United States and Canada for outstanding work in the life sciences industry.
Toshav’s national practice focuses on providing counsel to life sciences clients where she serves as a strategic advisor on a wide range of business and legal issues. Her experience covers the full spectrum of issues and transactions facing such companies and investors, including formation issues, public offerings, spin outs, corporate financings, mergers and acquisitions transactions and general corporate governance.
Toshav’s recent deals include representing Loxo Oncology in its $8 billion acquisition by Lilly, Audentes Therapeutics in its $3 billion acquisition by Astellas Pharma, Chinook Therapeutics in its merger with Aduro Biotech, and Modis Therapeutics in its acquisition by Zogenix. Over the last several months, Toshav also guided leading life sciences companies through significant public offerings, including Passage Bio’s $284.4 million IPO, Stoke Therapeutics’ $163 IPO and Morphic’s $103.5 million IPO. She also closed multiple public offerings for life sciences innovators such as Aeglea BioTherapeutics, Neoleukin Therapeutics and Sutro Biopharma.
In addition to her Corporate Lawyer of the Year honor, Toshav has been named a Life Sciences Star by LMG Life Sciences, highlighted by The Legal 500 among the nation’s leading capital markets lawyers, and honored as a shortlist finalist for the Best in Life Sciences at the Americas Women in Business Law awards.
The full list of LMG Life Sciences Americas Awards is available on the LMG Life Sciences website.